Austria
Brazil
Canada
Czech Republic
France
Germany
Hungary
Mauritius
Netherlands
Poland
Spain
Spanish Latin America
Switzerland
Australia
China
Japan
Malaysia
Philippines
Taiwan
Ethicare
Beta Healthcare
Kama
Nigeria
Shelys
Manufacturing Capabilites
PRIMARY SITES
Port Elizabeth, South Africa
Unit 1 facility
Capability:
High-volume solids manufacturing and packing for domestic and export markets.
Maximum output:
6 billion tablets
Accreditation:
ANVISA, FMHACA, GCC, ICHA, MCAZ, MHRA, NAFDAC, NDA, PMPB, PPB, SAHPRA, TFDA, TGA, US FDA, WHO.
Unit 3 facility
Capability:
End state packing for domestic market.
Maximum output:
140 million packed units of tablets and capsules.
Accreditation:
MCC and PIC/S.
Sterile facility SVP 1: multi-product suites A and B
Capability:
Eye drops, ampoules, vials; aseptic and terminal sterilisation capability for domestic and export markets.
Maximum output:
Suite A: Up to 42 million units of eye drops;
Suite B: Up to 25 million units of ampoules;
Up to 12 million units of liquid vials.
Accreditation:
LAsD, SAHPRA, US FDA, WHO.
Notre Dame de Bondeville, France
STERILE PREFILLED SYRINGE MANUFACTURING SITE
Capability:
Aseptic and terminally sterilised prefilled syringe manufacturing and packing for domestic and export markets.
Maximum output:
85 million syringes (Etna line); 130 million syringes (Stromboli line); 180 million syringes (Vesuve line) – (commercial production FY2020)
Accreditation:
ANSM, ANVISA, ASN, DQS, HPB, PMDA, US FDA.
Unit 2 facility
Capability:
Small to medium-volume solids manufacturing for domestic and export markets.
Maximum output:
4 billion tablets.
Accreditation:
ANVISA, FMHACA, GCC, ICHA, MCAZ, MCC, MHRA, NAFDA, NDA, PIC/S, PMPB, PPB, TFDA, TGA, US FDA, WHO.
Unit 4 facility
Capability:
Hormonal and highpotency solids manufacturing and packaging for the domestic and export markets.
Maximum output:
3,2 billion tablets (hormonal);
395 million tablets (potency).
Accreditation:
LAsD, SAHPRA. and US FDA.
Sterile facility SVP 2: high-potency suite
(commercial production FY2021)
Capability:
Liquid ampoules, vials and cartridges; emulsion ampoules, vials and cartridges; lyophilised vials; aseptic and terminal sterilisation capability for domestic and export markets.
Maximum output:
Suite C:
Up to 20 million vials;
Up to 25 million ampoules;
Up to 13 million cartridges.
Accreditation:
Regulatory inspections pending (project phase). LAsD tentatively planned, SAHPRA and TGA planned.
Bad Oldesloe, Germany
MULTI-DOSE FORM SITE
(Additional commercial production FY2021)
Capability:
Solid dose forms, oral and topical liquids, semi-solids and blow-fill seal, manufacturing and packing for domestic and export markets.
Maximum output:
3,3 billion tablets; 6 240 tonnes of liquids; 1 404 tonnes of topical liquids; 351 tonnes of semi-solids, 60 million units for blow-fill seals.
Accreditation:
ANVISA, GRA, IRA, LRA, PPB, PMDA, TGA, US FDA.
Sustaining a cost-competitive manufacturing base
Leveraging the Group’s diverse and specialist production capabilities
Our strategic objective of supplying high quality, affordable medicines and products is underpinned by our own manufacturing capabilities and the vertical integration of certain aspects of our supply chain. Our 25 manufacturing facilities present a range of production capabilities and capacities aligned with our current and future commercial objectives. These include injectables, oral solid and semi-solid dose, liquids, steriles, biologicals, APIs and nutritionals manufacturing. An overview of the Group’s strategic manufacturing capabilities is set out here.
During the last year, our strategic manufacturing projects continued to focus on the alignment of our facilities with our manufacturing and commercial strategies, enhancing technology and our quality and compliance standards, policies and procedures. Ongoing investment in the upgrading of our world-class manufacturing facilities as well as implementation of state of the art electronic systems ensures our ability to supply quality products, ensures ongoing compliance to GMP and creates increased manufacturing capacity to meet both current and future operational requirements. Capital expenditure on the replacement and expansion of property, plant and equipment amounted to R2 145 million (2017: R1 484 million) with a further R2 800 million planned for 2019.
Major projects underway to enable Aspen to manufacture anaesthetics
- Port Elizabeth - steriles
- Notre Dame de Bondeville – blow-fill seal
- Bad Oldesloe – creams, gels, liquids
PPE Capex - R'm
Approximately R2.8bn of PPE capex is also authorised for investment after FY 2019
Primary Sites
- Site-specific centres of production excellence
- Large-scale capabilities leading to COGS benefits
- Ensures uniform quality globally
- Specialist capabilities and skills
- Provide overall strategic advantage for Group
- Globally accredited
SOUTH AFRICA: One of our flagship manufacturing sites in Port Elizabeth, South Africa
API Facilities
- Biological capabilities including heparin where Aspen has become a significant global player
- Capabilities include biochemicals, peptides, steroid/hormones, high potency products and other chemicals
- Manufacturing capabilities enable control and access over niche pipeline opportunites
- Provides vertical integration advantage for Group
FRANCE: Our Notre Dame de Bondeville specialist sterile manufacturing site in Rouen, France
Regional Facilities
- Supply local/regional needs across diverse territories
HEAD OFFICE: Our Head Office in Durban, South Africa
HOLDINGS